BioPharma Credit PLC (LON:BPCR)
London · Delayed Price · Currency is GBP · Price in USD 0.9820
+0.0140 (1.45%)
Aug 14, 2026, 4:35 PM GMT
BioPharma Credit Revenue
In the year 2025, BioPharma Credit had annual revenue of $157.78M USD with 5.17% growth. BioPharma Credit had revenue of $73.98M in the half year ending December 31, 2025, with 29.30% growth.
Revenue
$157.78M
Revenue Growth
+5.17%
P/S Ratio
6.94
Revenue / Employee
n/a
Employees
n/a
Market Cap
813.40M GBP
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 157.78M | 7.76M | 5.17% |
| Dec 31, 2024 | 150.03M | 14.30M | 10.53% |
| Dec 31, 2023 | 135.73M | -82.41M | -37.78% |
| Dec 31, 2022 | 218.14M | 114.28M | 110.03% |
| Dec 31, 2021 | 103.86M | -6.15M | -5.59% |
| Dec 31, 2020 | 110.01M | -40.89M | -27.10% |
| Dec 31, 2019 | 150.89M | 53.61M | 55.11% |
| Dec 31, 2018 | 97.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jupiter Fund Management | 490.40M |
| Polar Capital Holdings | 263.60M |
| IntegraFin Holdings | 165.40M |
| Foresight Group Holdings | 164.92M |
| Molten Ventures | 159.30M |
| Pollen Street Group | 134.52M |
| Ashmore Group | 132.40M |
| Oakley Capital Investments | 80.91M |
BioPharma Credit News
- 5 months ago - BioPharma Credit Annual report: H2 2025 - Filings
- 5 months ago - BioPharma Credit Annual report: H2 2025 - Filings
- 5 months ago - BioPharma Credit Slides: H2 2025 - Filings
- 5 months ago - BioPharma Credit Slides: Investor presentation - Filings
- 11 months ago - BioPharma Credit Quarterly report: H1 2025 - Filings
- 11 months ago - BioPharma Credit Slides: H1 2025 - Filings